PCSA
Income statement / Annual
Last year (2023), Processa Pharmaceuticals, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, Processa Pharmaceuticals, Inc.'s net income was -$11.12 M.
See Processa Pharmaceuticals, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$5,000.00
|
$113,425.00
|
$200,201.00
|
| Cost of Revenue |
$222.00 |
$27.53 M |
$12.13 M |
$15.14 M |
$877,897.00 |
$630,092.00 |
$1,865.00 |
$1,381.00 |
$125,876.00 |
$113,251.00 |
| Gross Profit |
-$222.00 |
-$27.53 M |
-$12.13 M |
-$15.14 M |
-$877,897.00 |
-$630,092.00 |
-$1,865.00 |
$3,619.00 |
-$12,451.00 |
$86,950.00 |
| Gross Profit Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0.72 |
-0.11 |
0.43 |
| Research and Development
Expenses |
$5.80 M
|
$11.49 M
|
$6.88 M
|
$3.17 M
|
$2.32 M
|
$3.09 M
|
$926,117.00
|
$6,558.00
|
$29,246.00
|
$189,745.00
|
| General & Administrative
Expenses |
$5,657.54
|
$8.76 M
|
$4.69 M
|
$3.26 M
|
$1.61 M
|
$1.44 M
|
$876,316.00
|
$69,968.00
|
$945,460.00
|
$0.00
|
| Selling & Marketing
Expenses |
-$222.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$69,968.00
|
$945,460.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$5.66 M
|
$8.76 M
|
$4.69 M
|
$3.26 M
|
$1.61 M
|
$1.44 M
|
$876,316.00
|
$69,968.00
|
$945,460.00
|
$2.84 M
|
| Other Expenses |
-$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
-$69,968.00 |
-$945,460.00 |
$0.00 |
| Operating Expenses |
$11.46 M |
$20.26 M |
$11.57 M |
$6.44 M |
$3.94 M |
$4.52 M |
$1.80 M |
$76,526.00 |
$974,706.00 |
$3.03 M |
| Cost And Expenses |
$11.46 M |
$20.26 M |
$11.57 M |
$6.44 M |
$3.94 M |
$4.52 M |
$1.80 M |
$76,526.00 |
$1.10 M |
$3.15 M |
| Interest Income |
$0.00 |
$101,202.00 |
$11,989.00 |
$3,174.00 |
$11,548.00 |
$18,297.00 |
$5,181.00 |
$0.00 |
$4,651.00 |
$249.00 |
| Interest Expense |
$0.00 |
-$101,202.00 |
$362.00 |
$281,122.00 |
$36,658.00 |
$161,205.00 |
$35,693.00 |
$245,384.00 |
$235,644.00 |
$365,956.00 |
| Depreciation &
Amortization |
$222.00
|
$874,013.00
|
$875,349.00
|
$882,062.00
|
$877,897.00
|
$630,092.00
|
$1,865.00
|
$1,381.00
|
$238,822.00
|
$461,260.00
|
| EBITDA |
-$11.46 M
|
-$12.20 M
|
-$10.76 M
|
-$5.63 M
|
-$3.12 M
|
-$3.88 M
|
-$1.82 M
|
-$71,367.00
|
-$743,684.00
|
-$2.49 M
|
| EBITDA Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
-14.27 |
-6.56 |
-12.42 |
| Operating Income Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
14.31
|
23.73
|
-20.78
|
| Total Other
Income/Expenses Net |
$335,540.00
|
$101,202.00
|
$175,398.00
|
-$277,948.00
|
-$25,110.00
|
-$142,908.00
|
-$53,882.00
|
-$20,269.00
|
-$1.76 M
|
-$1.21 M
|
| Income Before Tax |
-$11.12 M |
-$27.42 M |
-$11.96 M |
-$15.41 M |
-$3.96 M |
-$4.67 M |
-$1.86 M |
-$337,179.00 |
-$2.98 M |
-$4.53 M |
| Income Before Tax Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-67.44
|
-26.3
|
-22.61
|
| Income Tax Expense |
-$2.00 |
$27.42 M |
-$530,611.00 |
-$1.00 M |
-$602,716.00 |
-$902,801.00 |
-$18,189.00 |
-$1,197.00 |
$100.00 |
$100.00 |
| Net Income |
-$11.12 M |
-$54.85 M |
-$11.43 M |
-$14.41 M |
-$3.36 M |
-$3.77 M |
-$1.86 M |
-$335,982.00 |
-$3.35 M |
-$4.53 M |
| Net Income Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
-67.2 |
-29.57 |
-22.61 |
| EPS |
-8.48 |
-68 |
-15 |
-38.4 |
-12.17 |
-14.2 |
-8 |
-29.8 |
-298.4 |
-500.8 |
| EPS Diluted |
-8.48 |
-68 |
-15 |
-38.4 |
-12.17 |
-14.2 |
-8 |
-29.8 |
-298.4 |
-500.8 |
| Weighted Average Shares
Out |
$1.31 M
|
$805,464.55
|
$765,973.15
|
$374,983.90
|
$275,868.00
|
$266,607.05
|
$232,826.05
|
$11,242.20
|
$11,237.25
|
$9,038.55
|
| Weighted Average Shares
Out Diluted |
$1.31 M
|
$805,464.55
|
$765,973.15
|
$374,983.90
|
$275,868.00
|
$266,607.05
|
$232,826.05
|
$11,242.20
|
$11,237.25
|
$9,038.55
|
| Link |
|
|
|
|
|
|
|
|
|
|
